Physician profile
William Pintauro
NPI 1548256373
$2,761.50
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,635 · 2020: $272 · 2021: $623 · 2022: $161 · 2023: $48.49 · 2024: $21.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $490.08 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $355.10 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $323.09 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $246.20 | 2021 | |
| Gilead Sciences, INC. | $245.73 | 2019 | |
| Antares Pharma, INC. | $209.89 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Medtronic USA, INC. | $124.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.99 | 2019 | |
| Amarin Pharma, INC. | $124.52 | 2019 | |
| Lilly USA, LLC | $124.46 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $124.31 | 2019 | |
| Esperion Therapeutics, INC. | $113.50 | 2021 | |
| Qol Medical, LLC | $66.25 | 2020 | |
| Janssen Biotech, INC. | $37.23 | 2021-2024 | Simponi Aria, Tremfya, Simponi |
| Abbvie INC. | $31.17 | 2019-2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $19.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Pintauro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.